Staging ::: VER CORREOS
España
Acceder

Farmas Orphan Drug

78 respuestas
Farmas Orphan Drug
Farmas Orphan Drug
Página
5 / 10
#34

Re: Farmas Orphan Drug

Gracias. Stormy, extenso pero interesante,esa Farma con Orphan Drug, es cuestión de unos meses segun el articulo, ya tengo un pack en ella,y quiero aumentar posición en mi otro broker pero me pide el codigo ISDIN,y no consigo sacarlo del primero ¡¿Podrias faciitarmelo.. ?. Gracias
Un saludo.

#36

Re: Farmas Orphan Drug

STORMY
MSTX
Muchas gracias, ya lo pase al broker, veo MB momento para entrar, el valor no cae y tiene volumen medio que no decrece por lo tanto creo que la oportunidad es ahora que están la cotizacion en un letargo pues las fechas de eventos importantes no son muy cercanas, pero semana antes empieza a calentarse y ya entramos en beneficios, mas aun con los 20 inversores institucionales que están dentro desde Junio 2013.

#37

Farmas Orphan Drug

Alguien sabe cuanto le queda a MSTX para ser delistada del NYSE por estar cotizando por debajo de 1 entero.. ?

Pues en Yahoo aparecen rumores de Reverse Split

#38

Re: Farmas Orphan Drug

MSTX no cotiza en el Nasdaq sino en AMEX así que no hay deslisting. Si hay reverse o no será por otros motivos, quizá buscando el ingreso en el Nasdaq en caso de recibier el orphan drug status.

#39

Re: Farmas Orphan Drug

Email del 15 de agosto, despues de una video conferencia,
NO TIENEN PLANTEADO , NI VOTADO DIVISIÓN NINGUNA , NI SPLIT NI REVERSE.( a la fecha de octubre)
En estos momentos y con la carga de institucionales , y la fuerza que tienen en la mesa de juntas, MSTX NO ES NINGUNEABLE.
"It was a pleasure to speak with you last week, we sincerely appreciate your continued consideration.
 
With regards to your first question, please note that Mast is not currently contemplating a reverse split of its shares. The NYSE MKT exchange is different from the NASDAQ & NYSE in that they do not have a specific minimum bid/target price requirement for listed companies to maintain, but rather have a policy regarding “Low Selling Price Issues – In the case of a common stock selling for a substantial period of time at a low price per share…” as part of their overall continued listing requirements.
 
With respect to your second set of questions, Mast currently owns the rights to MST-188 through the acquisition of SynthRx (the previous owner) – an acquisition that was completed in April of 2011. The payment terms of the merger agreement were structured in a way that the majority of the merger consideration would be payable only in the event of achievement of certain milestones. In connection with the closing of the merger, we issued approximately 2.8 million shares of common stock, of which 862,078 shares (or an approximately 3.3% ownership stake) are vested and approximately 1.9 million are unvested. The unvested shares will vest upon dosing of the first patient in a phase 3 clinical study meeting certain criteria, subject to reductions based on the timing of dosing of the first patient and the anticipated size of the study. Subsequent issuances of common stock are contingent upon successful achievement of developmental milestones consisting of (1) dosing of the first patient in a phase 3 clinical study meeting certain criteria, (2) acceptance by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) and (3) approval by the FDA of an NDA. Of the total shares issuable in connection with the acquisition, more than 75% are contingent upon the FDA accepting and approving an NDA covering MST-188 for the treatment of sickle cell crisis in children.
 
With regards to your third question, the Company is actively seeking partnerships/collaborations with not only potential pharma partners but also with the U.S. government to develop MST-188 in sickle cell disease (outside of the U.S.) as well as in other indications. As you may have seen, earlier this year we announced the engagement of ESC Advisors to serve as exclusive advisors to identify potential partners for MST-188 and advise the Company in transaction discussions.
 
Please let me know if you would like to schedule a short call to discuss these in greater detail or any other questions that you may have.
 
Best

#40

Re: Farmas Orphan Drug

Son muchos los parametros que hay que considerar para saber si MSTX realizará un RS.
En los contratos de adquisición de MST-188 seguramente nosotros no veremos la letra pequeña. Con lo cual solo nos queda la información que nos quieran dar sobre ello.
Saludos